BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37019410)

  • 21. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
    Vuong HG; Ngo TNM; Dunn IF
    Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.
    Tlemsani C; Larousserie F; De Percin S; Audard V; Hadjadj D; Chen J; Biau D; Anract P; Terris B; Goldwasser F; Pasmant E; Boudou-Rouquette P
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of cytofluorometric DNA ploidy analysis in distinguishing benign cartilaginous tumors from chondrosarcomas.
    Kusuzaki K; Murata H; Takeshita H; Hirata M; Hashiguchi S; Tsuji Y; Nakamura S; Ashihara T; Hirasawa Y
    Mod Pathol; 1999 Sep; 12(9):863-72. PubMed ID: 10496594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. H-ras oncogene mutation in dedifferentiated chondrosarcoma: polymerase chain reaction-restriction fragment length polymorphism analysis.
    Sakamoto A; Oda Y; Adachi T; Oshiro Y; Tamiya S; Tanaka K; Matsuda S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2001 Apr; 14(4):343-9. PubMed ID: 11301351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype.
    Cleven AH; Zwartkruis E; Hogendoorn PC; Kroon HM; Briaire-de Bruijn I; Bovée JV
    Histopathology; 2015 Oct; 67(4):483-90. PubMed ID: 25648524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones?
    Roitman PD; Farfalli GL; Ayerza MA; Múscolo DL; Milano FE; Aponte-Tinao LA
    Clin Orthop Relat Res; 2017 Mar; 475(3):808-814. PubMed ID: 26883651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy.
    Schoedel K; Heim T; Duensing A; Lohse I; Presutti L; Belayneh R; Bhogal S; Singh-Varma A; Chang A; Chandran U; Marker D; Szabo-Rogers H; Weiss K
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathomorphology of malignant chondrogenic bone tumors--an analysis of 94 cases from the Hamburg Bone Tumor Register (1974-1989)].
    Delling G; Welkerling H
    Z Orthop Ihre Grenzgeb; 1992; 130(1):1-8. PubMed ID: 1532267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IDH-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall.
    Sekita T; Yoshida A; Kawai A; Ichikawa H; Kobayashi E
    Genes Chromosomes Cancer; 2023 Dec; 62(12):755-760. PubMed ID: 37732625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synovial chondrosarcoma: a single-institution experience with molecular investigations and review of the literature.
    Gambarotti M; Pacheco M; Ruengwanichayakun P; Silvino Vega Jiménez B; Benini S; Bianchi G; Sbaraglia M; Vanel D; Carretta E; Bertoni F; Franchi A; Dei Tos AP; Righi A
    Histopathology; 2020 Sep; 77(3):391-401. PubMed ID: 32506447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.
    Amary MF; Ye H; Forbes G; Damato S; Maggiani F; Pollock R; Tirabosco R; Flanagan AM
    Virchows Arch; 2015 Feb; 466(2):217-22. PubMed ID: 25432631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant Cartilage-Forming Tumors.
    Hameed M
    Surg Pathol Clin; 2021 Dec; 14(4):605-617. PubMed ID: 34742483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrence analysis in 66 cases with grade I and grade II chondrosarcomas in the extremities.
    Ma XJ; Dong Y; Zhang CL; Zeng BF
    Orthop Surg; 2009 May; 1(2):132-6. PubMed ID: 22009830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chondrosarcoma of bone: an assessment of outcome.
    Lee FY; Mankin HJ; Fondren G; Gebhardt MC; Springfield DS; Rosenberg AE; Jennings LC
    J Bone Joint Surg Am; 1999 Mar; 81(3):326-38. PubMed ID: 10199270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH1 Mutation Induces HIF-1
    Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
    Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Status of IDH mutations in chondrosarcoma of the jaws.
    You Z; Zhang J; Zhang H; Li X; Sun Z; Sun L
    Int J Oral Maxillofac Surg; 2023 Jan; 52(1):26-31. PubMed ID: 35410781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chondrosarcoma: biology, genetics, and epigenetics.
    Chow WA
    F1000Res; 2018; 7():. PubMed ID: 30519452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: a population-based Scandinavian Sarcoma Group study of 106 patients.
    Widhe B; Bauer HC;
    J Thorac Cardiovasc Surg; 2009 Mar; 137(3):610-4. PubMed ID: 19258076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.
    van Oosterwijk JG; de Jong D; van Ruler MA; Hogendoorn PC; Dijkstra PD; van Rijswijk CS; Machado I; Llombart-Bosch A; Szuhai K; Bovée JV
    BMC Cancer; 2012 Aug; 12():375. PubMed ID: 22928481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
    Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
    Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.